Arcus Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Arcus Biosciences

07/08/2023 14:01

* Arcus Biosciences Inc  RCUS.N  reported a quarterly
adjusted
loss of $1.04​​ per share for the quarter ended in June. The
mean expectation of eleven analysts for the quarter was for a
loss of $1.10 per share.
    * Revenue rose 8.4% to $29.00 million from a year ago;
analysts
expected $30.30 million. 
    * Arcus Biosciences Inc's reported EPS for the quarter was a
loss
of $1.04​.
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Arcus Biosciences Inc shares had fallen by 6.4% this
quarter and
lost 8.0% so far this year.
    * The company reported a quarterly loss of $75 million.
    * Wall Street's median 12-month price target for Arcus
Biosciences
Inc is $40.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 01:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.10          -1.04          Beat
 Mar. 31 2023      -1.16          -1.09          Beat
 Dec. 31 2022      -1.07          -0.93          Beat
 Sep. 30 2022      -1.04          -0.90          Beat